2022 Clinic Disease Radiation Oncology 
Imaging Technology
APRIL 26, 2023
The guideline is published in Practical Radiation Oncology. The guideline emphasizes the need for a multidisciplinary team approach to guide treatment decisions for oligometastatic disease, a description for cancer that reaches a state in which the patient has a small number of metastases in addition to a primary tumor.
Imaging Technology
SEPTEMBER 27, 2023
milla1cf Wed, 09/27/2023 - 15:07 September 27, 2023 — The American Society for Radiation Oncology ( ASTRO ) announced the three winning research proposals for the 2022 ASTRO-Myovant Sciences (now known as Sumitomo Pharma)-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Imaging Technology
OCTOBER 2, 2023
milla1cf Mon, 10/02/2023 - 13:30 October 2, 2023 — A novel liquid biopsy test may help determine which patients with non-small cell lung cancer that has spread beyond the lungs are most likely to benefit from targeted, high-dose radiation, rather than drug-based therapy, a new study suggests. and worldwide. and worldwide. Chaudhuri explained.
Imaging Technology
OCTOBER 5, 2023
At the meeting, held from October 1 to October 4, 2023, in San Diego, Simon Powell, MD, PhD, FRCP , Chair of MSK’s Department of Radiation Oncology and Enid A. Haupt Chair in Radiation Oncology, was honored with ASTRO’s Gold Medal Award. It is caused by an inherited mutation in the gene TP53.
AuntMinnie
APRIL 4, 2024
Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging. When, in 2022, the U.S. Morris continued in the JNM.
AuntMinnie
JANUARY 26, 2024
Conversely, FAPI radiotracers such as gallium-68 (Ga-68) FAPI have been developed that bind to fibroblast cells in the supportive tissue of tumors, and these PET tracers have shown significant promise for detecting disease in previous studies. PET/CT and MR images of a 72-year-old woman. (A) but presented no evidence for primary tumor.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman. please insert video here.
Expert insights. Personalized for you.
77 
Let's personalize your content